Table 2. Virological outcomes and drug resistance, by study.
| Study | Follow-up
(weeks) |
N°
patients |
N° treatment
failures (%) |
N° virological
failures (%) |
N°
amplified |
N° patients
with resistance |
Resistance patterns
(one line per patient) * |
||
|---|---|---|---|---|---|---|---|---|---|
| 24
weeks |
48
weeks |
24
weeks |
48
weeks |
||||||
| DTG-Mono | |||||||||
| Katlama et al. | 24 | 28 | 4 (14.3) | - | 3 (10.7) | - | 3 | 3 |
E138K,G140A, Q148R
E92Q N155H |
| Wijting et al. | 48 | 96 | - | 11 (11.5) | 2 (2.1) | 8 (8.3) | 6 | 3 |
S230R
R263K N155H |
| Gubavu et al. | 24 | 21 | 0 | - | 0 | - | - | - | |
| Oldenbüttel
et al. |
24 | 31 | 2 (6.5) | - | 1 (3.2) | - | 1 | 1 | Q148H, G140S |
| Rokx et al. | 48 | 5 | 0 | 1 (20) | 0 | 1 (20.0) | 1 | 0 | |
| Rojas et al. | 24 | 31 | 1 (3.2) | - | 1 (3.2) | - | 1 | 0 | 118R ** |
| Lecompte et al. | 24 | 8 | 1 (12.5) | - | 0 | - | - | - | |
| Blanco et al. | 24 | 31 | 2 (6.5) | - | 2 (6.4) | - | 2 | 2 |
E138A, S147G, N155H,
Q148R 138K, 155H, 140S |
| DTG-3TC | |||||||||
| Borghetti et al. | 24 | 36 | 3 (8.3) | - | 0 | - | - | - | |
| Maggiolo et al. | 48 | 94 | 0 | 3 (3.2) | 0 | 0 | - | - | |
| Joly et al. | 48 | 104 | 1 (1.0) | 3 (2.9) | 1 (1.0) | 1 (1.0) | 0 | - | |
| Reynes et al. | 48 | 27 | 3 (11.1) | 3 (11.1) | 0 | 0 | - | - | |
| Blanco et al. | 24 | 29 | 1 (3.5) | - | 1 (3.4) | - | 1 | 0 | K70E
***, K219E
***,
G190R $, M230I $ |
| Maggiolo et al. | 48 | 203 | 0 | 12 (6.0) | 0 | 0 | - | - | |
| Taiwo et al. | 48 | 44 | 1 (2.3) | 3 (6.9) | 1 | 1 | 1 | 0 | |
| DTG-RPV | |||||||||
| Llibre et al. | 48 | 513 | - | 27 (5.3) | 1 (0.2) | 2 (0.4) | 2 | 1 | K101K/E |
| Gantner et al. | 24 | 116 | 11 (9.5) | - | 1 (0.9) | - | 0 | - | |
| Bonijoly et al. | 24 | 268 | - | 51 (19.0) | - | 4 (1.5) | - | - | |
| Revuelta et al. | 48 | 32 | - | 2 (6.5) | 0 | 0 | - | - | |
| DTG-ATV | |||||||||
| Riva et al. | 24 | 61 | 3 (4.9) | - | 0 | - | - | - | |
| Castagna et al. | 48 | 116 | 5 (4.3) | 6 (5.2) | - | 1 (0.9) | - | - | |
| DTG-DRV | |||||||||
| Navarro et al. | 48 | 27 | - | 2 (7.4) | 0 | 1 (3.7) | 1 | 0 | |
*bold: InSTI resistance
**in 7% of integrated DNA in PBMC
*** in ≤1.5% of integrated DNA in PBMC
$ in integrated DNA in PBMC